Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target
No preference
No preference
No preference

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT06083844IIHigh grade BRCA WT and HRD- ovarian cancer with surgically documented minimal residual disease after a complete response to first line therapyPhase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline TherapyTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03832855IAdvanced solid tumors with complete response after surgery and chemotherapyAssessing the Immunogenicity of pING-hHER3FL in Patients With Resected MalignanciesNCView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
pING-hHER3FLImmune response against cancer expressing ERBB3(HER3)Clinical Trials

If you have any questions or would like help with your search, please call us at: 858-657-0282 or email us at patientsupport@clearityfoundation.org.